Investigating the influence of HER2 low status in LBC

Biological behaviour of HER2-low BC is dependent on HR expressionПодробнее

Dr. Bloom Explains Situations Requiring HER2 RetestingПодробнее

Her2 Low Breast CancerПодробнее

Ongoing Monitoring l AML Explained #15Подробнее

Treatement of HER2 Low Breast CancerПодробнее

Dr. Marks on Investigational Antibody-Drug Conjugates in HER2+ Breast CancerПодробнее

CALGB 40601 Alliance: impact of dual HER2 targeting on pCRПодробнее

Gabriela Hempfling - I’ll Have What She’s Having (and Other Models of Consumer Behavior)Подробнее

LBCC - Alert SystemПодробнее

Transcriptional Landscape of Drug Response Guides the Design of Drug CombinationsПодробнее

Video 7: How to Link USLCI to the Electricity BaselineПодробнее

Addressing Key Targets in Advanced NSCLC: HER2-, HER3-, and TROP2-Targeted TherapiesПодробнее

The LSB and the wider legal sectorПодробнее

LBC discussion on regulation of therapists 19.10.24 2pmПодробнее

EBLL Response in Public Housing, Segment 3: Other Covered UnitsПодробнее

Facing Change: AML expectations of legal sector regulatorsПодробнее

Quick Chat on ESG Disclosure: Through the Lens of Corporate ReportingПодробнее

Litigating Capacity And Undue Influence - MCLE BY BHBAПодробнее